GlobalData on MSN2d
FDA approves AstraZeneca’s Imfinzi combo for bladder cancerThe US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody Imfinzi (durvalumab) with ...
The U.S. Food and Drug Administration (FDA) on Monday approved AstraZeneca Plc's (NASDAQ:AZN) Imfinzi (durvalumab) in ...
AstraZeneca has secured another expansion of its Imfinzi for use in cancer patients before and after surgery. | Imfinzi is ...
Approval of Imfinzi marks the first and only perioperative immunotherapy indicated for muscle-invasive bladder cancer.
The FDA has approved Imfinzi (durvalumab) as neoadjuvant and adjuvant treatment in patients with muscle-invasive bladder cancer.
The FDA approved neoadjuvant Imfinzi, gemcitabine and cisplatin, followed by adjuvant Imfinzi after radical cystectomy in ...
Based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death vs. neoadjuvant chemotherapy alone AstraZeneca’s IMFINZI ...
The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...
AstraZeneca’s IMFINZI® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by IMFINZI as adjuvant monotherapy after radical cystectomy (surgery to remove the ...
AstraZeneca (AZ) has announced that its Imfinzi (durvalumab) perioperative regimen has been approved by the US Food and Drug ...
AstraZenecas drug Imfinzi (NASDAQ: AZN) has received U.S. approval to treat adult patients with muscle-invasive bladder ...
Imfinzi was generally well tolerated, and no new safety signals were observed in the neoadjuvant and adjuvant settings.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback